MROQC

What MROQC does

MROQC (Michigan Radiation Oncology Quality Consortium) is a nonprofit Collaborative Quality Initiative (CQI) established in 2011 to improve the quality, value, and outcomes of radiation therapy for breast, lung, and prostate cancers and bone metastases across the state of Michigan. The consortium operates as a multi-stakeholder clinical data network, with 25-27 participating hospital-based and free-standing radiation oncology facilities and over 300 active members including clinical champions, radiation oncologists, medical physicists, dosimetrists, clinical data abstractors, and facility administrators. Its core technology is a comprehensive clinical data registry that captures patient-reported outcomes, physician toxicity assessments, and detailed radiation treatment delivery and dose data, organized into four disease-specific databases (Breast/Lung, Bone Mets, Prostate) and surfaced through Power BI-based facility performance, CDA, physics, and prostate matching dashboards. Supporting tools include the Pneumonitis Prediction App, Eclipse treatment planning templates, TG-263 nomenclature standards, clinical and physics data forms, and patient-facing resources covering tobacco cessation, cannabis education, and reirradiation.

MROQC's business model is fundamentally payer-funded rather than product-sold. The consortium is supported by Blue Cross Blue Shield of Michigan and Blue Care Network through the BCBSM Value Partnerships program, with participating facilities receiving annual FTE/Participation Payments tied to case volume at a benchmark of 181 patients per FTE, and with the potential to earn CQI Value-Based Reimbursement at 103-110% of the standard fee schedule through the PGIP program. The Coordinating Center is housed at Michigan Medicine, University of Michigan, with Program Director Dr. Lori Pierce and Co-Directors Dr. Bob Dess and Dr. Martha Matuszak providing clinical leadership, and a dedicated team of statisticians, health informaticists, and quality specialists operating the registry, analytics, and working groups (Breast, Lung, Mets, Prostate, and M-EQUAL). The go-to-market is community-led: facilities join through direct engagement with the Coordinating Center, commit to minimum case volumes (150+ new cases annually) and active participation, and engage through three annual collaborative-wide meetings plus monthly working group meetings.

Name

MROQC

Legal name

Michigan Radiation Oncology Quality Consortium

Website

https://mroqc.org

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

MROQC is a Michigan-based nonprofit Collaborative Quality Initiative, founded in 2011 and funded by Blue Cross Blue Shield of Michigan, that operates a clinical data registry and quality improvement program for radiation oncology across 25-27 facilities.

Ownership category

akta.pro rank

Product category

Radiation Oncology Quality Improvement

NAICS

Diagnostic Imaging Centers (621512)

SIC

Services-Health Services (8000)

akta.pro primary industry

Healthcare Master Data Management (MDM) & Patient/Provider Identity Data (HLACAIAB)

akta.pro secondary industry

Reference Data Management (RDM) (HDAEADAE)

Keywords

• Radiation oncology quality
• Clinical quality improvement
• Oncology collaborative consortium
• Value-based healthcare
• Radiation treatment registry

Headquarters

HQ city

Ann Arbor

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. BCBSM Value Partnerships Funding: MROQC receives funding through Blue Cross Blue Shield of Michigan's Value Partnerships program. Participating facilities receive annual Participation Payments for FTE funding based on case volume through BCBSM-BCN support.
2. FTE/Participation Payments: Facilities receive annual Participation Payments for full-time equivalent (FTE) funding based on their case volume. The model is based on 181 patients per FTE. Payments are distributed in July.
3. CQI Value-Based Reimbursement: MROQC is one of 13 CQIs offering CQI VBR to participating PGIP physicians based on meeting clinical targets. Physicians can receive 103-110% of the standard fee schedule.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

MROQC is a nonprofit quality consortium that operates clinical data registries and quality improvement programs for radiation oncology facilities across Michigan. It maintains cancer-specific databases (Breast, Lung, Bone Mets, Prostate), standardized treatment planning templates, and analytical dashboards, while facilitating collaborative working groups, best-practice dissemination, and integration with Blue Cross Blue Shield of Michigan value-based reimbursement programs.

Product overview

MROQC (Michigan Radiation Oncology Quality Consortium) is a quality consortium platform established in 2011 comprising a unified core platform of clinical data registries and databases for radiation oncology quality improvement, supported by multiple specialized modules and tools. The core consists of four cancer-specific databases (Breast/Lung, Bone Mets, Prostate) feeding into integrated dashboards (Facility Performance, CDA, Physics, Prostate Matching). Supporting modules include the Pneumonitis Prediction App, Clinical and Physics data forms, Eclipse treatment planning templates, Tobacco Cessation and Cannabis Education resource libraries, Patient Follow-up Calculator, and Reirradiation Resources. The consortium organizes five Working Groups (Breast, Lung, Mets, Prostate, M-EQUAL) to focus quality improvement efforts by cancer type.

Differentiator

Problem solved

Functional benefit

Products and services

• MROQC Clinical Data Registry Centralized clinical data registry maintained by the MROQC Coordinating Center that captures patient-reported outcomes, physician toxicity assessments, and radiation treatment delivery data for breast, lung, prostate cancers and bone metastases across participating Michigan facilities.
• MROQC Breast and Lung Database Dedicated database system for tracking and managing clinical data for breast and lung cancer radiation treatment cases at participating consortium facilities.
• MROQC Bone Mets Database Dedicated database for bone metastases patient data within the MROQC consortium, supporting palliative radiation treatment quality improvement.
• MROQC Prostate Database Database system for prostate cancer radiation treatment case data management, launched as part of the Prostate Working Group expansion.
• MROQC Facility Performance Dashboard Dashboard providing facility-level performance metrics including enrollment summary, demographics, and performance measures for participating facilities.
• MROQC Pneumonitis Prediction App Web-based tool for estimating risk of Grade 2 and Grade 3 pneumonitis in lung cancer patients, enabling clinicians to compare treatment plans and predict outcomes based on dosimetric and clinical parameters including Target Lung V5 Gy, Mean Lung Dose, smoking status, age, and comorbidities.
• MROQC Working Groups Specialized clinical working groups (Breast, Lung, Mets, Prostate, M-EQUAL) focused on quality improvement initiatives for specific cancer types, each led by physician and physics co-leads and meeting regularly to drive collaborative improvement.

Quantifiable outcome

• Reduced radiation treatment times for breast, lung, prostate cancers and bone metastases
• +1 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability1 record

Feature4 records

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Michigan Urological Surgery Improvement Collaborative (MUSIC): Sister Michigan CQI under BCBSM Value Partnerships, focused on urological care quality improvement. Operates an analogous consortium model with clinical data registry, value-based reimbursement, and coordinating center infrastructure, with explicit collaboration with MROQC's Prostate Working Group.
• Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI): Michigan CQI under BCBSM Value Partnerships focused on hip and knee arthroplasty quality. Operates with the same consortium model, hospital participation criteria, and payer-funded governance structure as MROQC.
• Michigan Surgical Quality Collaborative (MSQC): Michigan CQI under BCBSM Value Partnerships focused on general and vascular surgical quality. Competes with MROQC for the same pool of BCBSM Value Partnerships funding and uses an analogous data-registry-driven quality improvement model.
• Blue Cross Blue Shield Michigan Cardiovascular Consortium (BMC2): Another Michigan CQI under the same BCBSM Value Partnerships program covering percutaneous coronary intervention, vascular surgery, and cardiac surgery quality. Shares the CQI funding pool, VBR mechanism, and coordinating-center governance model with MROQC.

Broad incumbents

• National Cancer Institute SEER Program: NCI's authoritative population-based cancer registry covering incidence, treatment, and outcomes across the U.S. MROQC's disease-specific radiation therapy registry provides deeper treatment-level granularity than SEER for the cancer sites both cover.
• NRG Oncology (formerly RTOG): National NCI-sponsored clinical trial cooperative group for radiation oncology, covering many of the same disease sites (breast, lung, prostate). Operates at a much larger scale with multi-institutional trial infrastructure and overlapping leadership with academic radiation oncology.
• American Association of Physicists in Medicine (AAPM): National professional society for medical physicists that publishes the TG-263 nomenclature standard implemented by MROQC. MROQC leadership actively chairs AAPM task groups, making AAPM both a peer and a governing-standards partner.
• Imaging and Radiation Oncology Core (IROC): NCI-funded quality assurance core for radiation oncology clinical trials. Performs credentialing and dosimetry QA services that overlap with MROQC's physics data standardization and TG-263 nomenclature work.
• ASTRO (American Society for Radiation Oncology): National professional society for radiation oncology that sets clinical practice guidelines (which MROQC operationalizes) and operates the RO-ILS patient safety initiative. Provides the national standards framework that MROQC's quality measures are built upon.

Emerging players

• Radiation Oncology Incident Learning System (RO-ILS): National radiation-oncology-specific patient safety and incident learning system operated by ASTRO and AAPM. Overlaps with MROQC's quality improvement mission by capturing radiation therapy safety events across participating facilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/michigan-radiation-oncology-quality-consortium-mroqc
• Xx.com/mroqc1

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MROQC